This multi-centre randomised placebo-controlled trial will evaluate whether giving very preterm infants supplemental lactoferrin (a natural antibiotic protein from cow's milk) reduces the number of serious infections.
About 20% of very preterm infants (born before 32 weeks of gestation) acquire a serious infection in the neonatal unit.
Better methods of preventing infection in very preterm infants are needed.
ELFIN started with an internal pilot phase in 5 centres in the Northern Region and Yorkshire Neonatal Networks.
Feasibility was shown during this initial pilot phase in 6 months.
A total of 2,200 infants will now be recruited to participate in the trial over a four year period.
The main trial will invite participation from very preterm infants cared for in neonatal units across the UK.
Treatment will continue until the infants are no longer at high risk of acquiring serious infections (34 weeks postmenstrual age; a maximum of 70 days treatment will be given).
As well as comparing the incidence of serious infection between the two groups, we will also assess the effect on the incidence of other serious diseases and death, on the need for infants to receive multiple or prolonged courses of antibiotics (a major cause of antibiotic resistance in neonatal units), and on the length of hospital stay.
- Griffiths J, Jenkins P, Vargova M, Bowler U, Juszczak E, King A, Linsell L, Murray D, Partlett C, Patel M, Berrington J, Dorling J, Embleton ND, Heath PT, Oddie S, McGuire W, Ainsworth S, Boyle E, Clarke P, Craig S, Johnson K, Mactier H, Scorrer T, Ledwidge M, Story I, Holder G, Ohadike P, Ellis S, Vaikute R, Gowda G, Yates H, Garg S, Pilling E, Roehr C, Batra D, Gibson D, Johnson M, Kumar Y, Bartle D, Peters C, Quine D, Gupta R, Matthes J, Kennea N, Reynolds P, Geethanath R, Janakiraman S, Vasu V, Manjunatha CM. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. The Lancet. 2019;393(10170):423-33.